Silvant Capital Management LLC Sells 3,112 Shares of Cencora, Inc. $COR

Silvant Capital Management LLC lowered its holdings in Cencora, Inc. (NYSE:COR) by 8.6% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 32,898 shares of the company’s stock after selling 3,112 shares during the quarter. Silvant Capital Management LLC’s holdings in Cencora were worth $10,282,000 at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. Vanguard Group Inc. grew its stake in Cencora by 4.1% in the 3rd quarter. Vanguard Group Inc. now owns 23,395,547 shares of the company’s stock valued at $7,311,810,000 after purchasing an additional 916,506 shares during the period. State Street Corp lifted its stake in Cencora by 9.3% in the third quarter. State Street Corp now owns 9,190,316 shares of the company’s stock valued at $2,872,249,000 after purchasing an additional 782,911 shares during the last quarter. JPMorgan Chase & Co. grew its holdings in Cencora by 21.3% during the third quarter. JPMorgan Chase & Co. now owns 4,677,797 shares of the company’s stock valued at $1,461,965,000 after purchasing an additional 821,098 shares during the period. Boston Partners increased its position in Cencora by 2.0% in the third quarter. Boston Partners now owns 4,509,165 shares of the company’s stock worth $1,409,152,000 after buying an additional 89,506 shares during the last quarter. Finally, Wellington Management Group LLP grew its stake in shares of Cencora by 3.0% during the 3rd quarter. Wellington Management Group LLP now owns 3,971,121 shares of the company’s stock worth $1,241,094,000 after acquiring an additional 115,278 shares during the period. 97.52% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several research firms have commented on COR. Barclays upped their price objective on shares of Cencora from $400.00 to $425.00 and gave the company an “overweight” rating in a report on Friday, February 13th. JPMorgan Chase & Co. raised their price objective on shares of Cencora from $417.00 to $419.00 and gave the stock an “overweight” rating in a report on Tuesday, February 10th. Weiss Ratings upgraded shares of Cencora from a “hold (c+)” rating to a “buy (b)” rating in a research note on Thursday, February 5th. Robert W. Baird set a $415.00 target price on shares of Cencora in a report on Tuesday, January 13th. Finally, Bank of America lowered their price objective on Cencora from $380.00 to $360.00 and set a “neutral” rating on the stock in a research report on Monday, January 5th. Twelve research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $403.17.

Cencora Stock Down 3.2%

Shares of Cencora stock opened at $334.69 on Wednesday. The company has a debt-to-equity ratio of 3.62, a quick ratio of 0.51 and a current ratio of 0.92. Cencora, Inc. has a 52-week low of $260.23 and a 52-week high of $377.54. The company’s 50 day moving average price is $355.45 and its 200-day moving average price is $339.50. The stock has a market capitalization of $65.11 billion, a price-to-earnings ratio of 40.23, a P/E/G ratio of 1.61 and a beta of 0.68.

Cencora (NYSE:COR) last posted its quarterly earnings results on Wednesday, February 4th. The company reported $4.08 EPS for the quarter, beating analysts’ consensus estimates of $4.04 by $0.04. The company had revenue of $85.93 billion during the quarter, compared to analyst estimates of $86.12 billion. Cencora had a net margin of 0.50% and a return on equity of 176.54%. The firm’s revenue was up 5.5% compared to the same quarter last year. During the same period in the prior year, the business posted $3.73 EPS. Equities research analysts forecast that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, March 2nd. Stockholders of record on Friday, February 13th were issued a dividend of $0.60 per share. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.7%. The ex-dividend date was Friday, February 13th. Cencora’s dividend payout ratio is currently 28.85%.

Insider Buying and Selling

In other Cencora news, CEO Robert P. Mauch sold 5,096 shares of the stock in a transaction that occurred on Tuesday, January 20th. The stock was sold at an average price of $354.73, for a total value of $1,807,704.08. Following the completion of the sale, the chief executive officer owned 66,726 shares in the company, valued at approximately $23,669,713.98. This trade represents a 7.10% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Elizabeth S. Campbell sold 3,351 shares of Cencora stock in a transaction that occurred on Friday, December 19th. The stock was sold at an average price of $342.10, for a total value of $1,146,377.10. Following the completion of the sale, the executive vice president owned 23,891 shares in the company, valued at approximately $8,173,111.10. This represents a 12.30% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 15,220 shares of company stock valued at $5,282,867 over the last ninety days. 0.38% of the stock is owned by insiders.

About Cencora

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.